• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:02:53 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AVXL alert in real time by email
    SC 13G/A 1 anavexlife_13gam4dec2020.htm SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    ANAVEX LIFE SCIENCES CORP.

    (Name of Issuer)

     

    Common Stock, PAR VALUE $0.001 per share

    (Title of Class of Securities)

     

    032797300

     

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    [   ] Rule 13d-1(b)

    [X] Rule 13d-1(c)

    [   ] Rule 13d-1(d)

      

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     
     

     

    CUSIP No.  032797300
    (1) Names of Reporting Persons
      Park West Asset Management LLC  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Delaware  
    Number of Shares Beneficially Owned by Each Reporting Person With
      (5) Sole Voting Power: 0    
      (6) Shared Voting Power: 0    
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power: 0    
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      0  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      0.0%  
    (12) Type of Reporting Person (See Instructions):
      IA  
                   
                     

     

      

    CUSIP No.  032797300
    (1) Names of Reporting Persons
      Park West Investors Master Fund, Limited  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Cayman Islands  
    Number of Shares Beneficially Owned by Each Reporting Person With
      (5) Sole Voting Power: 0    
      (6) Shared Voting Power: 0    
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power: 0    
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      0  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      0.0%  
    (12) Type of Reporting Person (See Instructions):
      CO  
                   

     

     
     

      

    CUSIP No.  032797300
    (1) Names of Reporting Persons
      Peter S. Park  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      United States of America  
    Number of Shares Beneficially Owned by Each Reporting Person With
      (5) Sole Voting Power: 0    
      (6) Shared Voting Power: 0    
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power: 0    
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      0  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      0.0%  
    (12) Type of Reporting Person (See Instructions):
      IN  
                   

     

     
     

     

    Item 1(a).  Name of Issuer:  Anavex Life Sciences Corp. (the “Company”)
       
    Item 1(b).  Address of Issuer’s Principal Executive Offices:
     

    51 W 52nd Street, 7th Floor

    New York, NY 10019

     

    Item 2(a).  Name of Person Filing:
      This report on Schedule 13G (this “Schedule 13G”) is being jointly filed by (i) Park West Asset Management LLC, a Delaware limited liability company (“PWAM”), (ii) Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”) and (iii) Peter S. Park (“Mr. Park” and, collectively with PWAM and PWIMF, the “Reporting Persons”).  
    Item 2(b).  Address of Principal Business Office or, if None, Residence:
     

    The address for the Reporting Persons is:  900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939.

    Item 2(c).  Citizenship:
     

    PWAM is organized under the laws of the State of Delaware. PWIMF is a Cayman Islands exempted company. Mr. Park is a citizen of the United States.  

    Item 2(d).  Title of Class of Securities:
      Common Stock, par value $0.001 per share (“Common Stock”).
    Item 2(e).  CUSIP No.:
      032797300

     

     

    Item 3.  If This Statement Is Filed Pursuant to Rules 13d-1(b) or 13d-2(b) or (c), Check Whether the Person Filing is a:  
      Not Applicable.  

    Item 4.  Ownership: 

     
      As reported in the cover pages to this report, the ownership information with respect to each of PWAM and Mr. Park is as follows:      

     

      (a)     Amount Beneficially Owned: 0     
      (b)     Percent of Class: 0.0%     
      (c)     Number of Shares as to which such person has:      
      (i)     Sole power to vote or to direct the vote: 0    
      (ii)    Shared power to vote or to direct the vote: 0    
      (iii)   Sole power to dispose or to direct the disposition of: 0    
      (iv)   Shared power to dispose or to direct the disposition of: 0    
               

     

     

    As reported in the cover pages to this report, the ownership information with respect to PWIMF is as follows:

     

         
      (a)     Amount Beneficially Owned: 0     
      (b)     Percent of Class: 0.0%     
      (c)     Number of Shares as to which such person has:      
      (i)     Sole power to vote or to direct the vote: 0    
      (ii)    Shared power to vote or to direct the vote: 0    
      (iii)   Sole power to dispose or to direct the disposition of: 0    
      (iv)   Shared power to dispose or to direct the disposition of: 0    
               

     

     

     

     

    Item 5.  Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  [X]
    Item 6.  Ownership of More Than Five Percent on Behalf of Another Person:
      Not Applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
              Not Applicable.
    Item 8.  Identification and Classification of Members of the Group:
              Not Applicable.
    Item 9.  Notice of Dissolution of Group:
              Not Applicable.
    Item 10.  Certification:
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 16, 2021  
         
      PARK WEST ASSET MANAGEMENT LLC  
         
         
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer  

     

         
         
      PARK WEST INVESTORS MASTER FUND, LIMITED  
           
           

     

     

     By:   Park West Asset Management LLC, its

             Investment Manager

     
         
         
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer  
         
         

     

          /s/ Peter S. Park  
          Peter S. Park  
             
             

     

    Attention: Intentional misstatements or omissions of fact constitute

    Federal criminal violations (See 18 U.S.C. 1001)

     

       

     

     
     

    Exhibit Index

     

    Exhibit

     

    1.    Joint Filing Agreement dated as of February 14, 2018 by and among Park West Asset Management LLC, Park West Investors Master Fund, Limited and Peter S. Park (incorporated by reference to Exhibit A to the Schedule 13G filed with the Securities and Exchange Commission on February 14, 2018).

     

     

     

     

    Get the next $AVXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVXL

    DatePrice TargetRatingAnalyst
    12/6/2022$16.00 → $11.00Overweight → Neutral
    Cantor Fitzgerald
    6/23/2022$40.00Buy
    Berenberg
    2/2/2022$39.00 → $42.00Buy
    HC Wainwright & Co.
    9/23/2021$35.00Buy
    BTIG Research
    6/28/2021$25.00 → $39.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AVXL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Donhauser Peter D.O. bought $10,319 worth of shares (2,835 units at $3.64), increasing direct ownership by 131% to 5,000 units (SEC Form 4)

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      6/17/24 7:30:10 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Thomas Steffen bought $22,600 worth of shares (5,000 units at $4.52) (SEC Form 4)

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      5/17/24 6:01:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will participate at both the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference. Both conferences will take place in New York City (NY

      5/14/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

      Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its second quarter of fiscal 2025. "Anavex's portfolio with non-invasive targeted upstream precision compounds continues to advance with special focus on Alzheimer's disease and schizophrenia. We also co

      5/13/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its second fiscal quarter on Tuesday , May 13, 2025. Management will host a conference call on Tuesday, May 13, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Following managem

      5/6/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Leadership Updates

    Live Leadership Updates

    See more
    • Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

      NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board. Dr. Audrey Gabelle is a Professor of Neurology, MD, PhD, Neurologist and

      4/23/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences Announces Expansion of Leadership Team

      NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market. Reinforcing the Company's commitment to drive value-creation through operational efficiencies and innovation in the industry, Anavex announces n

      5/22/24 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences investors: Please contact the Portnoy Law Firm to recover your losses; May 13, 2024 deadline

      LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. Anavex is engaged in the research, production, and marketing of p

      5/1/24 6:31:25 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Anavex Life Sciences Corp.

      10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)

      5/13/25 4:31:17 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Anavex Life Sciences Corp.

      DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)

      4/25/25 4:35:45 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Anavex Life Sciences Corp.

      DEF 14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)

      4/25/25 4:31:01 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by PFO & Treasurer Boenisch Sandra

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      4/30/25 8:00:38 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President and CEO Missling Christopher U

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      4/30/25 8:00:22 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donhauser Peter D.O.

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      4/2/25 9:47:21 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Anavex downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Anavex from Overweight to Neutral and set a new price target of $11.00 from $16.00 previously

      12/6/22 9:27:26 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Berenberg initiated coverage on Anavex with a new price target

      Berenberg initiated coverage of Anavex with a rating of Buy and set a new price target of $40.00

      6/23/22 7:28:39 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Anavex Life Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $42.00 from $39.00 previously

      2/2/22 6:36:27 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Financials

    Live finance-specific insights

    See more
    • Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

      Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its second quarter of fiscal 2025. "Anavex's portfolio with non-invasive targeted upstream precision compounds continues to advance with special focus on Alzheimer's disease and schizophrenia. We also co

      5/13/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its second fiscal quarter on Tuesday , May 13, 2025. Management will host a conference call on Tuesday, May 13, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Following managem

      5/6/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

      Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. "We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing with potential c

      2/12/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

      SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

      2/13/24 4:58:52 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

      SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

      1/22/24 11:34:51 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

      SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

      2/9/23 11:07:31 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care